Staar Surgical Company ( (STAA) ) has released its Q1 earnings. Here is a breakdown of the information Staar Surgical Company presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
STAAR Surgical Company, a leader in the ophthalmic surgery sector, specializes in implantable phakic intraocular lenses (IOLs) for vision correction, leveraging its proprietary Collamer material for safe, long-term solutions. In the first quarter of 2025, STAAR Surgical reported a significant decline in net sales, primarily due to reduced channel inventory in China, while experiencing growth in other key markets. The company implemented cost control measures and restructuring activities to align expenses with sales, and it also undertook tariff mitigation strategies to address potential impacts on exports to China. Despite a net loss of $54.2 million, STAAR Surgical saw a 9% increase in net sales outside China, reflecting growth across all key markets. The gross margin decreased to 65.8% due to higher manufacturing costs and inventory reserves. Looking ahead, STAAR Surgical remains optimistic about resuming growth in revenue and Adjusted EBITDA in the second half of the year, driven by its strong technology, market share gains, and the increasing global incidence of myopia.